A Novel GJA5 Variant Associated with Increased Risk of Essential Hypertension

Juan Wang,Xue-Cheng Wang,Zhao-Hua Gu,Guang-Wei Ren,Xiao-Hong Zhao,Xin-Kai Qu,Ying-Jia Xu,Yi-Qing Yang
2023-01-01
Abstract:Objectives: Gap junction protein alpha 5 (GJA5), also termed connexin 40 (Cx40), exerts a pivotal role in the mediation of vascular wall tone and two closely-linked polymorphisms in the GJA5 promoter (-44G > A and +71A > G) have been associated with enhanced susceptibility to essential hypertension (EH) in men. The present investigation aimed to ascertain whether a novel common polymorphism within the upstream regulatory region of GJA5 (transcript 1B), -26A > G (rs10465885), confers an increased risk of EH. Methods: For this investigation, 380 unrelated patients with EH and 396 unrelated normotensive individuals employed as control persons were enrolled from the Chinese Han-ethnicity population, and their GJA5 genotypes and plasma renin concentrations were determined by Sanger sequencing and an automated chemiluminescent immunoassay, respectively. The functional effect of the GJA5 variant was explored in cultured murine cardiomyocytes by dual-light reporter gene analysis. Results: The GJA5 variant conferred a significantly increased risk for EH (OR: 2.156; 95% CL: 1.661-2.797, P < 0.0001), and significantly increased plasma renin levels were measured in patients with EH in comparison with control individuals (46.3 & PLUSMN;7.2 vs 37.4 & PLUSMN;6.9, P < 0.0001). A promoter-luciferase analysis revealed significantly diminished activity of the promoter harboring the minor allele for this variation in comparison with its wild-type counterpart (165.67 +/- 16.85 vs 61.53 +/- 8.67, P = 0.0007). Conclusions: These findings indicate that the novel variant upstream of the GJA5 gene (-26A > G) confers a significantly increased vulnerability of EH in humans, suggesting potential clinical implications for precisive prophylaxis and treatment of EH.
What problem does this paper attempt to address?